Esaxerenone

Exelixis to Release Third Quarter 2021 Financial Results on Tuesday, November 2, 2021

Tuesday, October 19, 2021 - 9:05pm

Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarter 2021 financial results will be released on Tuesday, November 2, 2021 after the markets close.

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarter 2021 financial results will be released on Tuesday, November 2, 2021 after the markets close.
  • At 5:00 p.m. EDT / 2:00 p.m. PDT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update.
  • For more information about Exelixis, please visit www.exelixis.com , follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.
  • Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered trademarks of Exelixis, Inc. MINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.

Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following FDA Acceptance of Investigational New Drug Application for Phase 1 Clinical Trial in Non-Hodgkin’s Lymphoma

Thursday, October 14, 2021 - 1:00pm

Exelixis has now assumed responsibility for the future clinical development, commercialization and global manufacturing of XL114.

Key Points: 
  • Exelixis has now assumed responsibility for the future clinical development, commercialization and global manufacturing of XL114.
  • Following the U.S. Food and Drug Administrations (FDA) recent acceptance of its Investigational New Drug (IND) application, Exelixis will soon initiate a phase 1 clinical trial evaluating XL114 monotherapy in patients with Non-Hodgkins lymphoma (NHL).
  • View the full release here: https://www.businesswire.com/news/home/20211014005549/en/
    XL114 is the second molecule that Exelixis in-licensed from Aurigene under the companies July 2019 collaboration, option and license agreement.
  • Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered trademarks of Exelixis, Inc. MINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.

Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes

Thursday, October 14, 2021 - 1:30pm

The collaboration will focus initially on ADAR1, advancing early work by STORM applying its proprietary RNA epigenetic platform, as well as explore an additional undisclosed target.

Key Points: 
  • The collaboration will focus initially on ADAR1, advancing early work by STORM applying its proprietary RNA epigenetic platform, as well as explore an additional undisclosed target.
  • "STORM has established industry-leading expertise and know-how through ground-breaking research on the discovery of small molecule therapies targeting RNA-modifying enzymes.
  • This collaboration with Exelixis validates the significant value of our technology platform and expanding pipeline," said Keith Blundy, Director and Chief Executive Officer, STORM Therapeutics.
  • Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered U.S. trademarks of Exelixis, Inc. MINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.

Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes

Thursday, October 14, 2021 - 1:30pm

ALAMEDA, Calif. and CAMBRIDGE, England, Oct. 14, 2021 /PRNewswire/ -- Exelixis, Inc. (Nasdaq: EXEL) and STORM Therapeutics (STORM) today announced that they have entered into an exclusive collaboration and license agreement under which the parties will discover and advance novel drug leads intended for the treatment of cancer. The collaboration will focus initially on ADAR1, advancing early work by STORM applying its proprietary RNA epigenetic platform, as well as explore an additional undisclosed target. 

Key Points: 
  • The collaboration will focus initially on ADAR1, advancing early work by STORM applying its proprietary RNA epigenetic platform, as well as explore an additional undisclosed target.
  • "STORM has established industry-leading expertise and know-how through ground-breaking research on the discovery of small molecule therapies targeting RNA-modifying enzymes.
  • This collaboration with Exelixis validates the significant value of our technology platform and expanding pipeline," said Keith Blundy, Director and Chief Executive Officer, STORM Therapeutics.
  • Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered U.S. trademarks of Exelixis, Inc. MINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.

Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes

Thursday, October 14, 2021 - 1:00pm

Exelixis, Inc. (Nasdaq: EXEL) and STORM Therapeutics (STORM) today announced that they have entered into an exclusive collaboration and license agreement under which the parties will discover and advance novel drug leads intended for the treatment of cancer.

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) and STORM Therapeutics (STORM) today announced that they have entered into an exclusive collaboration and license agreement under which the parties will discover and advance novel drug leads intended for the treatment of cancer.
  • STORM has established industry-leading expertise and know-how through ground-breaking research on the discovery of small molecule therapies targeting RNA-modifying enzymes.
  • This collaboration with Exelixis validates the significant value of our technology platform and expanding pipeline, said Keith Blundy, Director and Chief Executive Officer, STORM Therapeutics.
  • Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered U.S. trademarks of Exelixis, Inc. MINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.

Exelixis Statement on the Passing of Two Senior Executives

Monday, September 6, 2021 - 6:00pm

Exelixis President and Chief Executive Officer Michael M. Morrissey, Ph.D., issued the following statement on behalf of the Exelixis team and the companys Board of Directors:

Key Points: 
  • Exelixis President and Chief Executive Officer Michael M. Morrissey, Ph.D., issued the following statement on behalf of the Exelixis team and the companys Board of Directors:
    All of us at Exelixis are deeply, deeply saddened by Giselas passing.
  • Like Gisela, Jon was a wonderful friend and colleague, and his passing is an enormous loss to all who knew him and to the Exelixis family.
  • For more information about Exelixis, please visit www.exelixis.com , follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.
  • Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered trademarks of Exelixis, Inc. MINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.

Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in September

Wednesday, September 1, 2021 - 9:05pm

H.C. Wainwright 23rd Annual Global Investment Conference: Exelixis pre-recorded session will be available on-demand beginning 7:00am EDT / 4:00am PDT on Monday, September 13, 2021.

Key Points: 
  • H.C. Wainwright 23rd Annual Global Investment Conference: Exelixis pre-recorded session will be available on-demand beginning 7:00am EDT / 4:00am PDT on Monday, September 13, 2021.
  • BofA Securities Global Healthcare Conference: Exelixis is scheduled to present at 5:35pm BST / 12:35pm EDT / 9:35am PDT on Wednesday, September 15, 2021.
  • Cantor 2021 Virtual Global Healthcare Conference: Exelixis is scheduled to present at 2:40pm EDT / 11:40am PDT on Wednesday, September 29, 2021.
  • For more information about Exelixis, please visit www.exelixis.com , follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.

Exelixis and Invenra Expand Collaboration to Discover and Develop Novel Biologics in Oncology

Monday, August 16, 2021 - 1:05pm

As Exelixis seeks to build a differentiated next-generation pipeline in oncology, were leveraging Invenras expertise in antibody and bispecific discovery to provide key building blocks for potential future Exelixis biologics, including antibody-drug conjugates.

Key Points: 
  • As Exelixis seeks to build a differentiated next-generation pipeline in oncology, were leveraging Invenras expertise in antibody and bispecific discovery to provide key building blocks for potential future Exelixis biologics, including antibody-drug conjugates.
  • Our expanded collaboration with Invenra accelerates and deepens our work together and furthers Exelixis mission to pursue cancer therapies that help patients live longer and recover stronger.
  • Exelixis will own all antibody sequences discovered from the collaboration for all therapeutic uses in oncology and any other disease areas.
  • Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered U.S. trademarks of Exelixis, Inc.
    MINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.

Exelixis’ Collaborator Daiichi Sankyo Announces Positive Results From Phase 3 Pivotal Trial of Esaxerenone in Patients With Diabetic Nephropathy

Friday, November 8, 2019 - 1:01am

Exelixis, Inc. (Nasdaq: EXEL) announced today that its partner Daiichi Sankyo Company, Limited (Daiichi Sankyo) has reported positive results from a phase 3 pivotal trial of esaxerenone, a product of the companies prior research collaboration, in patients with diabetic nephropathy.

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) announced today that its partner Daiichi Sankyo Company, Limited (Daiichi Sankyo) has reported positive results from a phase 3 pivotal trial of esaxerenone, a product of the companies prior research collaboration, in patients with diabetic nephropathy.
  • Esaxerenone is a novel mineralocorticoid receptor (MR) blocker identified during the prior research collaboration between Exelixis and Daiichi Sankyo and subsequently developed and commercialized by Daiichi Sankyo.
  • Esaxerenone has been approved as a treatment for patients with hypertension in Japan, where it is marketed as MINNEBRO tablets.
  • Diabetic nephropathy is one of the most significant long-term complications in terms of morbidity and mortality for individual patients with diabetes.

Exelixis’ Collaborator Daiichi Sankyo Launches MINNEBRO® (Esaxerenone) Tablets in Japan

Monday, May 13, 2019 - 11:00am

Exelixis, Inc. (Nasdaq: EXEL) today announced its partner Daiichi Sankyo Company, Limited (Daiichi Sankyo) has launched MINNEBRO (esaxerenone) tablets as a treatment for patients with hypertension in Japan.

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) today announced its partner Daiichi Sankyo Company, Limited (Daiichi Sankyo) has launched MINNEBRO (esaxerenone) tablets as a treatment for patients with hypertension in Japan.
  • With Daiichi Sankyos first commercial sale of MINNEBRO, Exelixis will receive an associated $20 million milestone payment from Daiichi Sankyo under the terms of the companies collaboration agreement.
  • Daiichi Sankyos launch of MINNEBRO in Japan is an important advance for patients with hypertension in Japan, as well as for our two companies, said Michael M. Morrissey, Ph.D., President and Chief Executive Officer of Exelixis.
  • MINNEBRO is a novel mineralocorticoid receptor blocker identified during the prior research collaboration between Exelixis and Daiichi Sankyo and subsequently developed and commercialized by Daiichi Sankyo.